Question 1

What is DexCom's P/E ratio?

Accepted Answer

DexCom (DXCM) P/E ratio is 30.2× as of July 22, 2026. The ratio is calculated by dividing market capitalisation by trailing twelve-month earnings (net income), using USD-normalised financials (IAS 21 exchange-rate translation for non-USD reporters).

Question 2

How is the P/E ratio calculated?

Accepted Answer

P/E = Share Price ÷ Trailing Twelve-Month (TTM) Diluted EPS, or equivalently Market Capitalisation ÷ TTM Net Income. All inputs are sourced from audited GAAP/IFRS filings and translated to USD using period-end exchange rates so the multiple is comparable across companies and currencies.

Question 3

What is the P/E ratio?

Accepted Answer

The price-to-earnings (P/E) ratio, also called the earnings multiple, measures how much investors pay per dollar of a company's trailing twelve-month (TTM) earnings. It is calculated as share price ÷ TTM diluted EPS (equivalent to market capitalisation ÷ TTM net income). A higher P/E implies the market is pricing in stronger future earnings growth or lower risk; a lower P/E can signal slower expected growth, higher risk, or potential undervaluation.

Question 4

What is a good P/E ratio for DexCom?

Accepted Answer

There is no universal "good" P/E. As a rule of thumb, the S&P 500 has historically averaged a P/E in the mid-to-high teens; mature, slow-growth businesses commonly trade in the 10–18× range, while high-growth or asset-light companies often trade at 25–50×+. What matters is the comparison to sector peers and to the company's own historical range. For DexCom specifically, the relevant sector benchmark is the current sector median of 24.2×.

Question 5

Is DexCom's P/E ratio high or low?

Accepted Answer

DexCom's P/E ratio of 30.2× is below its own 5-year average of 105.8× and above the sector median of 24.2×. That places the current reading at the 3th percentile of its 10-year history. A higher multiple usually reflects stronger expected growth, lower perceived risk, or higher returns on capital; a lower multiple reflects the opposite.

Question 6

What is DexCom's historical P/E ratio range?

Accepted Answer

In the available daily series, DexCom (DXCM) P/E ratio has ranged from a low of 24.5× in 2026 to a high of 333.3× in 2022. The 5-year average is 105.8× and the 5-year median is 86.1×.

Question 7

What was DexCom's P/E ratio in 2025?

Accepted Answer

DexCom (DXCM) P/E ratio at the end of 2025 was 30.7×. Annual values reflect the multiple on the last trading day of each calendar year, using the trailing twelve-month earnings figure available at that date.

Question 8

Why does DexCom's P/E ratio change over time?

Accepted Answer

Valuation multiples move with two inputs: the numerator (market capitalisation, which tracks the share price) and the denominator (earnings). Share-price changes — driven by interest rates, earnings expectations, risk appetite, and broader market sentiment — typically dominate short-term moves, while changes in the underlying fundamental drive the longer-term trend. As a result, the ratio can rise during stock-price rallies even if the business itself has not become more valuable, and fall during sell-offs even when fundamentals are improving.


2025	$25.7B	$836M	30.7×	-23.2×	Dec 31, 2025
2024	$31.1B	$576M	53.9×	-34.1×	Dec 31, 2024
2023	$47.7B	$542M	88.0×	-40.2×	Dec 31, 2023
2022	$43.7B	$341M	128.2×	-208.5×	Dec 31, 2022
2021	$52.1B	$155M	336.7×	+266.0×	Dec 31, 2021
2020	$34.9B	$494M	70.7×	-127.5×	Dec 31, 2020
2019	$20B	$101M	198.2×	—	Dec 31, 2019
2018	$10.6B	-$127M	—	—	Dec 31, 2018
2017	$4.86B	-$50.2M	—	—	Dec 31, 2017
2016	$5.05B	-$65.6M	—	—	Dec 31, 2016
2015	$6.67B	-$57.6M	—	—	Dec 31, 2015
2014	$4.23B	-$22.4M	—	—	Dec 31, 2014
2013	$2.52B	-$29.8M	—	—	Dec 31, 2013
2012	$934M	-$54.5M	—	—	Dec 31, 2012
2011	$611M	-$44.7M	—	—	Dec 31, 2011
2010	$776M	-$55.2M	—	—	Dec 31, 2010
2009	$358M	-$53.5M	—	—	Dec 31, 2009
2008	$81.6M	-$55.2M	—	—	Dec 31, 2008
2007	$250M	-$45.9M	—	—	Dec 31, 2007
2006	$269M	-$46.6M	—	—	Dec 31, 2006
2005	$283M	-$30.8M	—	—	Dec 31, 2005


Medtronic (MDT)	22.2×
McKesson (MCK)	22.2×
Illumina (ILMN)	21.7×
ResMed (RMD)	21.6×
GE HealthCare (GEHC)	21.6×
Pfizer (PFE)	21.1×
Quest Diagnostics (DGX)	21.1×
Henry Schein (HSIC)	21.0×
AptarGroup (ATR)	20.9×
IQVIA (IQV)	20.7×
Biogen (BIIB)	19.7×
Zoetis (ZTS)	18.9×
Gilead Sciences (GILD)	18.8×
Humana (HUM)	18.5×
Regeneron Pharmaceuticals (REGN)	18.2×
Bristol-Myers Squibb (BMY)	17.0×
Elevance Health (ELV)	17.0×
HCA Healthcare (HCA)	15.8×
AstraZeneca (AZN)	14.7×
DaVita (DVA)	13.3×
Incyte (INCY)	13.1×
Cigna (CI)	11.1×
Novo Nordisk (NVO)	8.6×
Solventum (SOLV)	7.9×
Universal Health Services (UHS)	7.2×

P/E Ratio for DexCom (DXCM) 2019-2026

P/E Ratio daily chart for DexCom (DXCM)

Historical P/E Ratio for DexCom (DXCM) from 2005 to 2025

About P/E Ratio at DexCom (DXCM)

DexCom P/E Ratio by Year

DexCom P/E Ratio 2025: 30.7×

DexCom P/E Ratio 2024: 53.9×

DexCom P/E Ratio 2023: 88.0×

DexCom P/E Ratio 2022: 128.2×

DexCom P/E Ratio 2021: 336.7×

Sector peers by P/E Ratio — chart

Sector peers by P/E Ratio — table

Frequently asked questions

DexCom (DXCM) Key Financials